Core Viewpoint - UBS has initiated a "Buy" rating for Guoshengtang with a target price of HKD 48.3, forecasting a compound annual growth rate (CAGR) of 20% for adjusted earnings from 2024 to 2027 [1] Summary by Relevant Categories Company Growth Potential - UBS believes that investors may underestimate Guoshengtang's advantages in attracting doctors, managing policy risks, and serving chronic disease patients from public hospitals [1] - The company's sustainable growth is supported by its expertise in traditional Chinese medicine and value-added services [1] Market Opportunities - There are favorable opportunities for Guoshengtang to enhance doctor coverage and productivity [1] - The company is expanding its self-paid value-added services by leveraging its strengths in the traditional Chinese medicine supply chain, talent, and technology to mitigate policy risks [1]
瑞银：给予固生堂“买入”评级 目标价48.3港元